^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MK-3475 SC

    i
    Associations
    News

    Trials

    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (NCT03665597)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/10/2025
    Initiation :
    11/19/2018
    Primary completion :
    12/04/2023
    Completion :
    12/04/2023
    BRAF • TNFRSF9
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • MK-3475 SC
    Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) (NCT03313778)
    Phase 1
    ModernaTX, Inc.
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    08/14/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • ALK • TMB
    |
    EGFR mutation • ALK positive • ALK translocation • EGFR positive
    |
    Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)
    Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) (KEYNOTE-A86) (NCT04956692)
    Phase 3
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    08/05/2021
    Primary completion :
    04/04/2023
    Completion :
    10/14/2026
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • MK-3475 SC